Literature DB >> 23083850

Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model.

Alexander Kutikov1, Brian L Egleston, Daniel Canter, Marc C Smaldone, Yu-Ning Wong, Robert G Uzzo.   

Abstract

PURPOSE: Multiple risks compete with cancer as the primary cause of death. These factors must be considered against the benefits of treatment. We constructed a model of competing causes of death to help contextualize treatment trade-off analyses in patients with localized renal cell carcinoma.
MATERIALS AND METHODS: We identified 6,655 individuals 66 years old or older with localized renal cell carcinoma in the linked SEER (Surveillance, Epidemiology and End Results)-Medicare data set for 1995 to 2005. We used Fine and Gray competing risks proportional hazards regression to predict probabilities of competing mortality outcomes. Prognostic markers included race, gender, tumor size, age and the Charlson comorbidity index score.
RESULTS: At a median followup of 43 months, age and comorbidity score strongly correlated with patient mortality and were most predictive of nonkidney cancer death, as measured by concordance statistics. Patients with localized, node negative kidney cancer had a low 3 (4.7%), 5 (7.5%) and 10-year (11.9%) probability of cancer specific death but a significantly higher overall risk of death from competing causes within 3 (10.9%), 5 (20.1%) and 10 years (44.4%) of renal cell carcinoma diagnosis, depending on comorbidity score.
CONCLUSIONS: Informed treatment decisions regarding patients with solid tumors must integrate not only cancer related variables but also factors that predict noncancer death. We established a comorbidity based predictive model that may assist in patient counseling by allowing quantification and comparison of competing risks of death in patients 66 years old or older with localized renal cell carcinoma who elect to proceed with surgery.
Copyright © 2012 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23083850      PMCID: PMC4659779          DOI: 10.1016/j.juro.2012.07.100

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  27 in total

1.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

2.  The assessment of patient life-expectancy: how accurate are urologists and oncologists?

Authors:  James R M Wilson; Michael G Clarke; Paul Ewings; John D Graham; Ruaraidh MacDonagh
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

3.  A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.

Authors:  Hendrik Van Poppel; Luigi Da Pozzo; Walter Albrecht; Vsevolod Matveev; Aldo Bono; Andrzej Borkowski; Jean-Marie Marechal; Laurence Klotz; Eila Skinner; Thomas Keane; Ilse Claessens; Richard Sylvester
Journal:  Eur Urol       Date:  2006-11-15       Impact factor: 20.096

4.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives.

Authors:  P S Romano; L L Roos; J G Jollis
Journal:  J Clin Epidemiol       Date:  1993-10       Impact factor: 6.437

5.  Cure me even if it kills me: preferences for invasive cancer treatment.

Authors:  Angela Fagerlin; Brian J Zikmund-Fisher; Peter A Ubel
Journal:  Med Decis Making       Date:  2005 Nov-Dec       Impact factor: 2.583

6.  Rising incidence of small renal masses: a need to reassess treatment effect.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

7.  Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram.

Authors:  A Kutikov; M R Cooperberg; A T Paciorek; R G Uzzo; P R Carroll; S A Boorjian
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-06-19       Impact factor: 5.554

8.  Cancer and comorbidity in older patients: a descriptive profile.

Authors:  R Yancik; R J Havlik; M N Wesley; L Ries; S Long; W K Rossi; B K Edwards
Journal:  Ann Epidemiol       Date:  1996-09       Impact factor: 3.797

9.  Complexities in prognostication in advanced cancer: "to help them live their lives the way they want to".

Authors:  Elizabeth B Lamont; Nicholas A Christakis
Journal:  JAMA       Date:  2003-07-02       Impact factor: 56.272

10.  A competing-risks nomogram for sarcoma-specific death following local recurrence.

Authors:  Michael W Kattan; Glenn Heller; Murray F Brennan
Journal:  Stat Med       Date:  2003-11-30       Impact factor: 2.373

View more
  29 in total

Review 1.  Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry.

Authors:  Matthew R Danzig; Peter Chang; Andrew A Wagner; Mohamad E Allaf; James M McKiernan; Phillip M Pierorazio
Journal:  Curr Urol Rep       Date:  2016-01       Impact factor: 3.092

2.  Assessing the burden of complications after surgery for clinically localized kidney cancer by age and comorbidity status.

Authors:  Jeffrey J Tomaszewski; Robert G Uzzo; Alexander Kutikov; Katie Hrebinko; Reza Mehrazin; Anthony Corcoran; Serge Ginzburg; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Marc C Smaldone
Journal:  Urology       Date:  2014-04       Impact factor: 2.649

3.  Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy.

Authors:  Serge Ginzburg; Robert Uzzo; Tahseen Al-Saleem; Essel Dulaimi; John Walton; Anthony Corcoran; Elizabeth Plimack; Reza Mehrazin; Jeffrey Tomaszewski; Rosalia Viterbo; David Y T Chen; Richard Greenberg; Marc Smaldone; Alexander Kutikov
Journal:  J Urol       Date:  2013-07-27       Impact factor: 7.450

4.  Immunosuppressive effect of renal cell carcinoma on phenotype and function of dendritic cells.

Authors:  Lichen Teng; Yongsheng Chen; Dexin Ding; Hongshuang Dai; Guobin Liu; Changfu Li
Journal:  Int Urol Nephrol       Date:  2013-11-08       Impact factor: 2.370

5.  A Simple Method for Evaluating Within Sample Prognostic Balance Achieved by Published Comorbidity Summary Measures.

Authors:  Brian L Egleston; Robert G Uzzo; J Robert Beck; Yu-Ning Wong
Journal:  Health Serv Res       Date:  2014-12-18       Impact factor: 3.402

6.  Kidney cancer: Emerging guidelines for managing small renal masses.

Authors:  Benjamin T Ristau; Marc C Smaldone
Journal:  Nat Rev Urol       Date:  2017-03-14       Impact factor: 14.432

7.  Organ-sparing procedures in GU cancer: part 1-organ-sparing procedures in renal and adrenal tumors: a systematic review.

Authors:  Raouf Seyam; Mahmoud I Khalil; Mohamed H Kamel; Waleed M Altaweel; Rodney Davis; Nabil K Bissada
Journal:  Int Urol Nephrol       Date:  2019-01-08       Impact factor: 2.370

8.  Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis.

Authors:  Adam D Talenfeld; Renee L Gennarelli; Elena B Elkin; Coral L Atoria; Jeremy C Durack; William C Huang; Sharon W Kwan
Journal:  Ann Intern Med       Date:  2018-06-26       Impact factor: 25.391

9.  Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation.

Authors:  Alp Tuna Beksac; Gerant Rivera-Sanfeliz; Catherine A Dufour; Unwanaobong Nseyo; Zachary Hamilton; Sean W Berquist; Abd-elRahman Hassan; Omer A Raheem; Song Wang; Robert W Wake; Robert E Gold; Ithaar H Derweesh
Journal:  World J Urol       Date:  2016-08-02       Impact factor: 4.226

10.  Balancing cardiovascular (CV) and cancer death among patients with small renal masses: modification by CV risk.

Authors:  Hiten D Patel; Max Kates; Phillip M Pierorazio; Mohamad E Allaf
Journal:  BJU Int       Date:  2014-07-27       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.